Sep 2026· International Journal of Nanomedicine· Vol 21· 0 citations· 200 references
Medicine
TL;DR
A comprehensive overview of probiotic-derived EVs, including their biogenesis, classification, and molecular composition, is provided, with a focus on barrier regulation, immune modulation, and microbial homeostasis in IBD.
Abstract
Abstract Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory disorder driven by complex interactions. Despite therapeutic advances, achieving sustained remission remains difficult, underscoring the need for safer and more durable treatment strategies. Increasing evidence highlights the pivotal role of the gut microbiota in IBD pathogenesis, prompting growing interest in microbiome-based interventions. Probiotic-derived extracellular vesicles (probiotic-derived EVs), a subset of bacterial EVs (BEVs), have emerged as promising cell-free mediators of host–microbe communication. These nanoscale vesicles can deliver bioactive cargo, modulate immune responses, and influence epithelial barrier function, thereby offering a potential strategy to regulate intestinal homeostasis while potentially avoiding some limitations associated with live microbial therapies. This review provides a comprehensive overview of probiotic-derived EVs, including their biogenesis, classification, and molecular composition. It further examines their biological functions and mechanisms of action in IBD, with a focus on barrier regulation, immune modulation, and microbial homeostasis. Recent advances in engineering strategies to enhance therapeutic efficacy are also summarized. Key challenges for clinical translation, including standardization, safety concerns, and limited clinical validation despite promising preclinical findings, are discussed. Together, these mechanistic and translational perspectives help delineate the current evidence, remaining limitations, and future directions regarding the development of probiotic-derived EVs as nanotherapeutic platforms for IBD.
The modulation of gut microbiota is critical for intestinal homeostasis and addressing disorders such as inflammatory bowel disease (IBD) and colorectal cancer (CRC). Probiotics have gained attention for maintaining gut health, but ensuring their survival until reaching the target intestinal area remains a significan...
Xue-Qing Chen, L. Du, Jie Shen et al.· Regenerative Biomaterials· 0 citations
Current evidence regarding the role of gut microbiota-derived EVs in representative neurological, cardiovascular, and metabolic diseases is summarized, highlighting both their detrimental and beneficial effects.
Zhi-Ying Rao, Lin-Wei Li, Ying Liang et al.· Clinical and Translational G...· 0 citations
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder that increases the risk of colitis-associated colorectal cancer (CAC). Despite major advances in biologics and small-molecule therapies, many patients experience primary or secondary treat...
Min-Rui Huang, Jin-Tao Yuan, Peter Muro et al.· Frontiers in Immunology· 0 citations
To overcome biopharmaceutical bottlenecks, an overview of nanozyme-based intelligent delivery platforms tailored for the inflamed gut are provided, covering endogenous/exogenous stimuli-responsive, biomimetic, and microbiota-mediated systems.
Extracellular vesicles (EVs) have been shown to be key regulators of intestinal homeostasis and inflammatory responses, offering new insights into the pathogenesis of inflammatory bowel disease (IBD) and the development of targeted therapeutic strategies. EVs in the intestine can be secreted by intestinal epithelial ce...
Yiyi Lv, Qian Yang, Xi-Xi Cai et al.· Autoimmunity Reviews· 0 citations